BJMO - volume 18, issue 2, march 2024
H. Van Poppel MD, PhD
The 15th European Multidisciplinary Congress on Urological Cancers (EMUC23) took place in Marseille, France, from 2 to 5 November 2023, bringing together various medical specialists dedicated to the care of genitourinary (GU) cancer patients. Expert medical oncologists, radiation oncologists, pathologists, nuclear medicine specialists, urologists and radiologists participated in the multidisciplinary panel discussions. This article aims to provide an overview of the GU cancer diagnosis, treatment updates, and case discussions deliberated during the congress.
(Belg J Med Oncol 2024;18(2):65–7)
Read moreBJMO - volume 18, issue 2, march 2024
L. Decoster MD, PhD, C. Kenis PhD, MSc
The annual meeting of the International Society of Geriatric Oncology (SIOG) unites each year different health care workers involved in the treatment of older patients with cancer with the goal of improving personalised care. This year, recent advances in the field of geriatric oncology were discussed, including randomised controlled trials and ASCO guidelines for the implementation of comprehensive geriatric assessment.
(Belg J Med Oncol 2024;18(2):68–70)
Read moreBJMO - volume 18, issue 1, february 2024
I. Demedts MD, PhD, J. Van Meerbeeck MD, PhD, A. Awada MD, PhD, T. Berghmans MD, PhD
All.Can Belgium is multi-stakeholder, non-profit organisation working to improve the efficiency of cancer care by focusing on what matters to patients. In this spirit, they bring together healthcare professionals, representatives from patient organisations, policymakers, researchers, and the pharmaceutical industry. Over the last decade, we have witnessed a dramatic evolution in the treatment landscape for patients with lung cancer. However, to have a more profound impact on the lung cancer burden, these therapeutic advances need to be coupled with effective strategies for lung cancer screening, prevention, and patient support. By leveraging on the collaboration between healthcare professionals, patient organisations, policy makers and the pharmaceutical industry, the Lung Cancer Working Group established by All.Can Belgium wants to address the most prominent needs in the care pathway for patients with lung cancer. On the 16th of November 2023, the official launch of the Lung Cancer Working Group was celebrated with a symposium coupling lectures on pertinent issues in lung cancer with patient testimonials.
(BELG J MED ONCOL 2024;18(1):33–9)
Read moreBJMO - volume 17, issue 4, june 2023
W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, O. Islam MD, S. Chhajlani MD, I. Van der Massen MSc, N. Ahmadi Bidakhvidi MD, C.M. Deroose MD, PhD
The 2023 edition of the European Neuroendocrine Tumour Society (ENETS) congress was held in Vienna between 22nd and 24th March. This article aims to provide an overview of the most remarkable findings and insights presented during this congress.
(BELG J MED ONCOL 2023;17(4):139–49)
Read moreBJMO - volume 17, issue 3, may 2023
W. Lybaert MD, A. Demols MD, PhD
This year’s conference was organised in San Francisco from 19 until 21 January 2023, again as a hybrid event. It was an excellent meeting, not with the immune checkpoint inhibitors in gastroesophageal cancer in first position this time, like last year, but with two new promising targeted therapies in that tumour type: zolbetuximab and regorafenib. Immunotherapy is also pushing more in the neoadjuvant setting of MSI-high local/locally advanced gastric/gastroesophageal junction tumours. NALIRIFOX is a new chemotherapy scheme that beats gemcitabine + nab-paclitaxel in first-line metastatic pancreatic cancer, while the addition of nab-paclitaxel to cisplatin + gemcitabine in first-line advanced biliary tract cancer brings no advantage. Finally, yet importantly, trifluridine/tipiracil + bevacizumab outperforms trifluridine/tipiracil alone in later-line metastatic colorectal cancer. The combination of botensilimab + balstilimab is also very promising in this more refractory disease setting.
In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2023;17(3):91–9)
Read moreBJMO - volume 16, issue 6, october 2022
H. Van Poppel MD, PhD, G. Salomon MD
The 13th European Multidisciplinary Congress on Urological Cancers (EMUC21) and the 9th Meeting of the EAU Section of Urological Imaging (ESUI21), two events where interdisciplinary expertise and innovation culminated, took place in Athens, Greece from 25 to 28 November 2021. This article provides a collective report of the events’ vital updates and hot topics covered.
(BELG J MED ONCOL 2022;16(6):307–9)
Read moreBJMO - volume 16, issue 6, october 2022
W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, O. Islam MD, I. Van der Massen MSc, I. Karfis MD, PhD, H. Eggers , M. Peeters MD, PhD
The first World NET Forum brought together leading scientists in the neuroendocrine tumour (NET) field to present their cutting-edge research to inspire other scientists and clinicians. This meeting focused mainly on models in NET research, NET tumour biology, as well as therapeutic and diagnostic advances. This article discusses some of the most relevant and promising studies.
(BELG J MED ONCOL 2022;16(6):310–22)
Read more
Top
